Combination of metformin with liraglutide in treating HAIR-AN syndrome in children<b>:</b> A case report and literature review.
Zhong Nan Da Xue Xue Bao Yi Xue Ban · 2023
Last updated 2026-05-28A child with HAIR-AN syndrome—a rare condition involving high androgen levels, insulin resistance, and skin changes—showed significant improvement in obesity, blood sugar control, menstrual irregularities, and skin darkening after treatment with metformin and liraglutide. The case highlights that unexplained skin darkening and menstrual issues may signal HAIR-AN syndrome, and early treatment can help.
AI summary of the abstract below.
| Journal | Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2023 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.67 |
| NIH percentile | 37 |
| Molecules | liraglutide |
| Conditions studied | Obesity, Pcos |
Abstract
Hyperandrogenism-insulin resistance-acanthosis nigricans (HAIR-AN) syndrome is a special and rare subtype of polycystic ovarian syndrome. It can lead to hyperandrogenism (HA), insulin resistance (IR), and acanthosis nigricans (AN) accompanied by acne, hirutism, irregular menstruation, and other androgen excess symptoms. A case of pediatric HAIR-AN syndrome with severe AN was admitted to the Department of Endocrinology, China-Japan Friendship Hospital. The patient's clinical manifestations, laboratory data, imaging features, and gene sequencing were analyzed, and the patient was diagnosed with pediatric HAIR-AN syndrome. Obesity, IR, hyperglycemia, menstrual disorder, and AN were significantly improved after treating with metformin and liraglutide. HAIR-AN syndrome occurs in various forms. When the patient appears unexplained acanthosis nigricans and menstrual disorders, the disease should be considered possible. Early diagnosis and symptomatic supportive treatment can improve the quality of life.
Verbatim abstract via PubMed 38044655 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.